info@seagull-health.com
SeagullHealth
search
Gilteritinib(Xospata)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Gilteritinib(Xospata) Instructions:Uses,Dosage, Side Effects
XOSPATA, with the generic name gilteritinib, is an oral kinase inhibitor developed for the treatment of acute myeloid leukemia. It is specifically designed to target and inhibit the FMS-like tyrosine kinase 3 (FLT3) receptor, which is a key driver of disease progression in a specific genetic subset of AML. The drug is formulated as a 40 mg film-coated tablet for once-daily administration.
XOSPATA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation as detected by an FDA-approved test.
Recommended dose: 120 mg orally once daily, with or without food.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
